Dermata Therapeutics, Inc. entered into a private placement on August 16, 2026, raising approximately $3.4 million in gross proceeds and an estimated $3.2 million net of expenses. The company issued 933,064 shares of common stock and pre-funded warrants for 1,360,544 additional shares at $1.46 per share to institutional investors, alongside Series E and F warrants exercisable at $1.46 per share. Company insiders contributed approximately $2.4 million at a slightly higher price of $1.47 per unit. Proceeds will fund general corporate purposes, including the launch of a new OTC acne kit on August 25, 2026, and potential acquisitions. The company operates in the dermatologic solutions industry, focusing on direct-to-consumer skincare products.

Dermata Therapeutics announced the anticipated launch date for its first commercial product, Tome Foundational Treatment, via a press release on August 5, 2026. The company expects sales to begin on August 25, 2026, with early access for waitlisted customers. The treatment set consists of four once-weekly applications and will be sold exclusively online at www.tomeskincare.com for $178, equating to approximately $45 per treatment. This marks a strategic shift toward commercializing skincare products to accelerate the path to revenue generation. Dermata Therapeutics operates in the dermatology and consumer healthcare industry, developing and marketing topical treatments for skin conditions.